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Abstract
Background: Cysteinyl leukotriene (CysLT) is one of the proinflammatory mediators released by the bronchi during
inflammation. CysLTs exert their biological effects via specific G-protein-coupled receptors. CysLT1 receptor antagonists are
available for clinical use for the treatment of asthma. Recently, crosstalk between CysLT1 and P2Y6 receptors has been
delineated. P2Y receptors are expressed in apical and/or basolateral membranes of virtually all polarized epithelia to control
the transport of fluid and electrolytes. Previous research suggests that CysLT1 receptor antagonists inhibit the effects of
nucleotides acting at P2Y receptors. However, the detailed molecular mechanism underlying the inhibition remains
unresolved.
Methodology/Principal Findings: In this study, western blot analysis confirmed that both CysLT1 and P2Y6 receptors were
expressed in the human bronchial epithelial cell line 16HBE14o-. All three CysLT1 antagonists inhibited the uridine
diphosphate (UDP)-evoked ISC, but only montelukast inhibited the UDP-evoked [Ca
2+]i increase. In the presence of forskolin
or 8-bromoadenosine 3’5’ cyclic monophosphate (8-Br-cAMP), the UDP-induced ISC was potentiated but was reduced by
pranlukast and zafirlukast but not montelukast. Pranlukast inhibited the UDP-evoked ISC potentiated by an Epac activator, 8-
(4-Chlorophenylthio)-29-O-methyladenosine-39,59-cyclic monophosphate (8-CPT-29-O-Me-cAMP), while montelukast and
zafirlukast had no such effect. Pranlukast inhibited the real-time increase in cAMP changes activated by 8-CPT-29-O-Me-
cAMP as monitored by fluorescence resonance energy transfer imaging. Zafirlukast inhibited the UDP-induced ISC
potentiated by N
6- Phenyladenosine- 39,5 9- cyclic monophosphorothioate, Sp- isomer (Sp-6-Phe-cAMP; a PKA activator) and
UDP-activated PKA activity.
Conclusions/Significance: In summary, our data strongly suggest for the first time that in human airway epithelia, the three
specific CysLT1 receptor antagonists exert differential inhibitory effects on P2Y6 receptor-coupled Ca
2+ signaling pathways
and the potentiating effect on ISC mediated by cAMP and Epac, leading to the modulation of ion transport activities across
the epithelia.
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Introduction
Bronchial asthma is an inflammatory disease that affects millions
of people worldwide. Among the proinflammatory mediators
released by the bronchi are cysteinyl leukotrienes (CysLTs). They
are lipid mediators derived from arachidonic acid by the 5-
lipoxygenase (5-LO) pathway [1] and play critical roles in the
pathogenesis of asthma [2,3]. CysLTs exert their biological effects
via specific G-protein-coupled receptors. To date, there are two
cloned human CysLT receptor subtypes, namely CysLT1 and
CysLT2 [4]. Specific CysLT1 receptor antagonists, such as
montelukast, pranlukast, and zafirlukast, are available for clinical
use for the treatment of asthma [5]. Recently, crosstalk between
CysLT1 receptor and P2Y6 receptor signaling systems has been
reported in human mast cells [6] and monocyte/macrophage-like
cells [7]. P2Y6 is a member of the P2Y receptor family that is
expressed in the apical and/or basolateral membranes of virtually
all polarized epithelia to control the transport of fluid and
electrolytes [8,9]. It has been shown that uridine diphosphate
(UDP), a selective agonist for the P2Y6 receptor, can also activate
the CysLT1 receptor. On the other hand, CysLT1 receptor
antagonists could inhibit the effects of the extracellular nucleotide
acting at P2Y receptors [10]. Evidence also suggests that CysLTs
and UDP do not share the same receptor and the CysLT1 receptor
possesses dual CysLT/UDP specificity.
In the airway, chloride (Cl
2) secretion and sodium (Na
+)
reabsorption can be modulated by the activation of multiple P2Y
receptors that couple to the phospholipase C (PLC) and calcium-
signalingpathway.Recently, work fromthislaboratory has confirmed
that a human bronchial epithelial cell line, 16HBE14o-, expresses
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receptor [11]. UDP could stimulate both calcium (Ca
2+)- and 39,59-
cyclic monophosphate (cAMP)-dependent chloride ion secretion in
16HBE14o- cells. An increase in cAMP production could in turn
activate both protein kinase A (PKA) and an exchange protein
directly activated by cAMP (Epac) [12]. As there is little knowledge
regarding the effects of specific CysLT1 receptor antagonists on
airway epithelial transport, the aim of this project was to examine
their effects on P2Y6 receptor-mediated Cl
2 s e c r e t i o ni nah u m a n
bronchial epithelial cell line (16HBE14o-) and to investigate the
possible signal transduction pathway(s) through which the antagonists
may act.
Results
Expression of CysLT1 and P2Y6 receptors in the
16HBE14o- cell monolayer
To examine the presence of CysLT1 and P2Y6 receptors in
16HBE14o- cells, western blot analysis was conducted. The
protein expression of CysLT1 and P2Y6 receptors in 16HBE14o-
cells was detected as shown in Fig. 1. The CysLT1 receptor
polyclonal antibody identified an intense 44-kDa band in whole
cell lysates of 16HBE14o- cell monolayers (Fig. 1A, left lane). The
specificity of the band was confirmed by the complete abolishment
of the immunoreactive signal in 16HBE4o- cells by the CysLT1
receptor polyclonal antibody that had been preadsorbed with
specific blocking peptides. The blocking peptides correspond to
amino acid residues 318–337 of the human CysLT1 receptor
(Fig. 1A, right lane). On the other hand, the P2Y6 receptor was
identified as an intense 41-kDa band (Fig. 1B, left lane). The
specificity of the band was confirmed by the complete abolishment
of the immunoreactive signal by the P2Y6 receptor antibody
preadsorbed with specific blocking peptides. The blocking peptides
correspond to amino acid residues 322–343 of the human P2Y6
receptor (Fig. 1B, right lane). Western blot analysis demonstrated
that 16HBE14o- cells expressed CysLT1 receptors and confirmed
our previous finding on P2Y6 receptor expression in this cell line
[11].
Activation of the P2Y6 but not the CysLT1 receptor
stimulated increases in ISC and [Ca
2+]i in 16HBE14o- cells
UDP is the specific agonist of the P2Y6 receptor [13,14], which
has been shown to regulate ion transport processes in airway
epithelial cells via both Ca
2+- and cAMP-dependent pathways
[11]. First, the effect of apical application of UDP on ISC was
investigated using a conventional Ussing chamber study. Fig. 2A
shows the representative recordings of ISC in response to the apical
application of 30–300 mM UDP. The addition of UDP to the
apical side rapidly increased ISC. The ISC change consisted of
biphasic responses, namely an initial transient peak (first peak) and
a second increase within 2 min (second peak). In another series of
experiments, the intracellular calcium concentration was mea-
sured in 16HBE14o- cells grown on glass coverslips by using a
fluorescent technique. Fig. 2B shows the representative recordings
of [Ca
2+]i in response to 30–300 mM UDP application. The
changes in [Ca
2+]i were obtained by measuring the maximal
increase of the 340/380 nm fluorescence ratio upon stimulation.
Fig. 2C and 2D summarize the change of ISC (DISC) and
fluorescence ratio (Dratio) induced by UDP application, respec-
tively. Apical application of UDP elicited a concentration-
dependent increase in the first peak of ISC, with a UDP
concentration of 100 mM eliciting the maximal increase in ISC.
The increase in the second peak of ISC also exhibited a
concentration-dependent relationship with the apical application
of UDP, again with 100 mM UDP eliciting the maximal increase
in ISC. The addition of basolateral UDP evoked only a small and
variable increase in ISC in both phases (data not shown). Due to the
small response of basolateral UDP-induced ISC, only ISC induced
by apical addition of UDP was investigated further. The increase
in [Ca
2+]i upon the addition of UDP also exhibited concentration
dependency, again with 100 mM UDP inducing the largest
increase in [Ca
2+]i. In our previous study, the UDP-induced
[Ca
2+]i increase was abolished and the increase in ISC response was
greatly attenuated when the cells were treated with BAPTA-AM,
an intracellular Ca
2+ chelator. The results therefore confirmed our
previous findings that UDP could stimulate a calcium-dependent
ISC in 16HBE14o- cells [11].
Although CysLT1 receptor protein was expressed in 16HBE14o-
cells, activation of the receptor by its agonists, CysLT C4 (LTC4)o r
LTD4 [15], did not stimulate any discernible increase in [Ca
2+]i and
had no effect on the subsequent increase in Fura-2 ratio induced by
UDP (UDP alone: 0.06060.004; +LTC4: 0.04960.005; +LTD4:
0.05260.004, p.0.05). As shown in Fig. 2E, the presence of LTC4
or LTD4 also did not affect the basal ISC and the subsequent UDP-
evokedISC(UDPalone:29.362.1 mA/cm
2;+LTC4:22.462.4 mA/
cm
2; +LTD4: 21.664.8 mA/cm
2, n=6, p.0.05). It appears that
16HBE14o- cells do not possess functional CysLT1 receptors that
couple to the calcium-signaling pathway and thus did not exhibit
any changes in ISC.
CysLT1 receptor antagonists inhibited UDP-evoked ISC
The functional relationships between the CysLT and P2Y
receptors have been highlighted in several recent reports. For
example, it has been shown that CysLT1 receptor antagonists
inhibit the effects of nucleotides acting at P2Y receptors in U937
cells [10]. Therefore, the effect of three commonly used CysLT1
antagonists (montelukast, pranlukast, and zafirlukast) on P2Y6
receptor-coupled ISC was measured in 16HBE14o- cells. The
Figure 1. Western blotting analysis showing the protein expression of CysLT1 and P2Y6 receptors in 16HBE14o- cells. The expression
of CysLT1 (44 kDa) and P2Y6 (41 kDa) receptors was demonstrated (lane 1), and their positions on the blot closely matched their calculated molecular
masses of 39 kDa and 36 kDa, respectively. Detection of these protein bands appeared specific, as they were mostly blocked by prior reabsorption of
the antibodies with their respective control antigen for 2 h at 4uC (lane 2).
doi:10.1371/journal.pone.0022363.g001
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of CysLT1 antagonists at the apical side, followed by apical
application of 100 mM UDP. Addition of montelukast, pranlukast
or zafirlukast (up to 3 mM) alone did not stimulate any increase in
ISC. Fig. 3A shows the representative recordings of ISC in response
to the application of 100 mM UDP in the absence (control) or
presence of montelukast (1 mM). Fig. 3B summarizes the changes
of the first and second peaks of ISC in response to the application of
100 mM UDP after apical pretreatment with montelukast. In the
presence of apical montelukast (0.7, 1, and 3 mM), the UDP-
induced first peak was significantly reduced. The second peak of
ISC was not affected by montelukast.
Similar responses were obtained when the epithelia were
stimulated with UDP in the presence of pranlukast (Fig. 3C) or
Figure 2. Concentration-dependent effect of UDP on ISC and [Ca
2+]i. (A) Epithelia were initially bathed in normal K-H solution while changes
in ISC were recorded. A serosal-to-mucosal-directed Cl
2 gradient was applied across the monolayers by changing the apical K-H solution to one with
reduced Cl
2 concentration to facilitate Cl
2 secretion (not shown). Different concentrations of UDP were added to the apical side as indicated. Data
presented are representative of at least four independent experiments. (B) UDP-evoked increases in [Ca
2+]i were monitored by a microfluorimetric
technique using the calcium-sensitive fluorescent dye Fura-2. Cells grown on glass coverslips were initially superfused with normal K-H solution. The
K-H solution was then changed to a nominally Ca
2+-free K-H solution, and the cells were stimulated with different concentrations of UDP as indicated.
Data presented are representative of at least four independent experiments. (C) Concentration-response relationship for the effect of UDP upon DISC
in 16HBE14o- epithelia. The changes in ISC for the first and second peaks were quantified and plotted against the concentration of UDP used. Each
data point represents the mean 6 S.E. (n=4–5). (D) Concentration-response relationship for the effect of UDP upon changes in [Ca
2+]i represented by
Dratio. Each data point represents the mean 6 S.E. (n=4–5). (E) Application of CysLT1 receptor agonists (10 mM), LTC4 or LTD4, did not cause any
discernible increase in ISC and did not affect the subsequent 100-mM UDP-evoked ISC responses. Data presented are representative of at least four
independent experiments.
doi:10.1371/journal.pone.0022363.g002
CysLT1 Receptor Antagonists and P2Y6 Receptor
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22363zafirlukast (Fig. 3E). The UDP-induced first ISC peak was
significantly inhibited by apical pretreatment of the epithelia with
1 and 3 mM pranlukast (Fig. 3D) or zafirlukast (Fig. 3F). Again, the
UDP-induced second ISC peak was not inhibited by the apical
application of pranlukast or zafirlukast. For the highest concen-
tration of CysLT1 receptor antagonists tested (3 mM), approxi-
mately 50% of the UDP-evoked first peak of ISC was inhibited. All
three CysLT1 receptor antagonists failed to inhibit the apical
UDP-evoked ISC (first and second peaks) when applied to the
basolateral aspect of the epithelia (data not shown). Similar
experiments were conducted using a P2Y2/P2Y4 agonist, UTP
(100 mM). Interestingly, all three CysLT1 receptor antagonists
(1 mM) failed to inhibit the UTP (P2Y2/P2Y4)-mediated increase
in ISC (control: 9.760.9 mA/cm
2; +montelukast: 8.661.8 mA/cm
2;
+pranlukast: 8.861.0 mA/cm
2; +zafirlukast: 9.261.3 mA/cm
2,
n=5, p.0.05). Although P2Y1 receptors are expressed in
16HBE14o- cells [11], their specific agonist 2-methio- adenosine
diphosphate (100 mM) failed to elicit any increase in ISC (n=4).
Montelukast, but not pranlukast and zafirlukast, inhibited
UDP-evoked [Ca
2+]i increase in 16HBE14o- cells
Because UDP could elicit a calcium-dependent increase in ISC,
we tested whether the three CysLT1 antagonists could inhibit
UDP-evoked calcium signals. Addition of montelukast, pranlukast
Figure 3. Effect of CysLT1 receptor antagonists, montelukast, pranlukast, and zafirlukast, on UDP-evoked ISC responses.
Representative recordings of ISC in response to the apical application of 100 mM UDP (shown by arrows) in the presence of montelukast (A). The
CysLT1 receptor antagonist was applied 10 min before the application of UDP (data not shown). Data are summarized for the inhibitory effects of
montelukast (B) on the first and second peaks of ISC increases in response to UDP. Similar experiments were performed using pranlukast (C and D) or
zafirlukast (E and F). The control was the apical application of UDP alone in the absence of any CysLT1 receptor antagonist. Each column represents
the mean 6 S.E. (n=4–5). (*, p,0.05, one-way ANOVA with Bonferroni post-hoc test compared with control).
doi:10.1371/journal.pone.0022363.g003
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[Ca
2+]i. The UDP-induced [Ca
2+]i was reduced by 17.562.2%,
50.962.9%, and 56.163.4% in the presence of 0.7, 1, and 3 mM
montelukast, respectively (Fig. 4A). In contrast to the effect of
montelukast, the UDP-induced [Ca
2+]i was not significantly
reduced by pranlukast and zafirlukast up to 3 mM. Therefore,
although all three CysLT1 antagonists could inhibit UDP-evoked
ISC, pranlukast and zafirlukast failed to cause any inhibitory effects
on calcium signals evoked by UDP. Similar experiments were
conducted using the P2Y2/P2Y4 agonist UTP (100 mM) to
stimulate the cells. All three CysLT1 receptor antagonists (1 mM)
failed to inhibit the UTP (P2Y2/P2Y4)-mediated increase in
[Ca
2+]i (control: 0.01560.001 unit; +montelukast: 0.01360.001
unit; +pranlukast: 0.01660.001 unit; +zafirlukast: 0.01760.001
unit, n=5, p.0.05). The P2Y1 receptor agonist 2-methio-
adenosine diphosphate (100 mM) did not cause any discernible
increase in [Ca
2+]i (n=4).
The increase in [Ca
2+]i evoked by UDP is caused by the
coupling of P2Y6 receptors to PLC and hence the production of
the inositol trisphosphate (IP3) [13]. To test the effect of
montelukast on P2Y6 receptor-dependent calcium signaling, two
pharmacological agents, U73122 and xestospongin C (XeC), were
used. U73122 is a specific inhibitor of PLC [16], whereas XeC is a
novel blocker of the IP3 receptor [17]. In the experiment, the cells
were perfused with normal K-H solution containing 2.5 mM
Ca
2+, which was then changed to a nominally Ca
2+-free K-H
solution. XeC in various concentrations was added 10 min before
the application of 100 mM UDP. Under the pretreatment of the
epithelia with 0.1, 1 or 3 mM XeC, the UDP-induced [Ca
2+]i
response was reduced to 73.761.7, 50.663.5, and 1.161.0% of
the control response (Fig. 4B), respectively. Similarly, U73122 (0.1,
1, 3 mM) reduced the UDP-induced [Ca
2+]i response to 64.463.5,
40.765.6, and 5.262.1% of the control response, respectively.
The data demonstrated that P2Y6 receptors are coupled to the
PLC/IP3 signaling pathway, leading to an increase in [Ca
2+]i.
To test whether montelukast could interfere with the PLC/IP3
signaling pathway, experiments were performed by coincubation
of the 16HBE14o- cells with both montelukast (1 mM) and XeC
(0.1 mM). In the presence of montelukast and XeC, the UDP-
induced [Ca
2+]i response was reduced to 71.963.2% of the
control response, which is not statistically different from the
response in the presence of XeC alone (n=6,p.0.05). Therefore,
coincubation of XeC and montelukast failed to cause additional
inhibition of the UDP-induced [Ca
2+]i increase. The data suggest
that montelukast may interfere with the signaling pathway at a
level upstream of the IP3-induced Ca
2+ release. To investigate
whether montelukast may act upstream of the IP3-induced Ca
2+
release, the epithelia were coincubated with both U73122
(0.1 mM) and montelukast (1 mM). Similarly, the data demonstrat-
ed that coincubation of the epithelia with both U73122 and
montelukast reduced the UDP-induced [Ca
2+]i response to
63.262.6% of the control response, which is not statistically
different from that in the presence of U73122 alone (n=5,
p.0.05). Taken together, the data suggest that montelukast may
interfere with the calcium-signaling pathway at a level upstream of
PLC activity and the production of IP3.
CysLT1 antagonists inhibited the UDP-evoked Cl
2
secretion in the presence of cAMP elevating agents, Epac
or PKA activator
It has been shown recently by several studies that activation of
P2Y6 receptors leads to the activation of Ca
2+- and cAMP-
dependent Cl
2 secretion across airway epithelial cells [11,18,19],
possibly by increasing cellular cAMP production [11,20]. Increases
in cAMP production could in turn activate two downstream
signaling molecules, PKA and exchange protein directly activated
by cAMP (Epac) [12], which could then regulate epithelial Cl
2
secretion [21]. In this study, the effect of CysLT1 receptor
antagonists on the potentiating effect of cAMP-elevating agents
(forskolin, 8-Br-cAMP) and specific Epac [8-(4-Chlorophenylthio)-
29-O-methyladenosine-39,59-cyclic monophosphate; 8-CPT-29O-
Me–cAMP] and PKA [N
6- Phenyladenosine- 39,5 9- cyclic
monophosphorothioate, Sp- isomer; Sp-6-Phe-cAMP] activators
was examined. The potentiator was added about 10 min prior to
the application of UDP.
In the first series of experiments, general cAMP elevating agents,
suchas forskolin and 8-Br-cAMP were employed. As shown inFig. 5,
forskolin (1 mM) greatly potentiated both the first and second peaks of
ISC induced by UDP. The percentage increases of the first and second
peaks were 198.069.2% (UDP: 17.5061.95 mA/cm
2; +Forskolin:
34.7562.40 mA/cm
2, p,0.05, n=4–6) and 120.0613.4% (UDP:
21.3063.90 mA/cm
2; +Forskolin: 25.6062.85 mA/cm
2, p,0.05,
n=4–6), respectively. Similarly, 8-Br-cAMP, a cAMP analog,
potentiated the first and second peaks of ISC to 165.54613.78%
(+8-Br-cAMP: 28.9663.80 mA/cm
2, p,0.05, n=4–6) and
Figure 4. Effect of CysLT1 receptor antagonists, montelukast, pranlukast, and zafirlukast on UDP-evoked [Ca
2+]i responses. (A) Cells
were stimulated with UDP in the absence (control) or presence of different concentrations of CysLT1 receptor antagonists applied 10 min prior to the
addition of UDP (100 mM). (B) The UDP-evoked [Ca
2+]i responses were inhibited by different concentrations of an IP3 receptor antagonist, XeC, or a
PLC inhibitor, U73122. Each column represents the mean 6 S.E. (n=4–6). (*, p,0.05, one-way ANOVA with Bonferroni post-hoc test compared with
control).
doi:10.1371/journal.pone.0022363.g004
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2, p,0.05, n=4–
6), respectively.
Forskolin and 8-Br-cAMP are general cAMP level elevators that
cannot distinguish between their two downstream targets, PKA
and Epac. Therefore, in the second series of experiments, specific
Epac or PKA activator were used. 8-CPT-29-O-Me-cAMP and
Sp-6-Phe-cAMPs were thus employed to potentiate the UDP-
induced ISC. 8-CPT-29-O-Me-cAMP is a specific activator of Epac
[22] that potentiated the first peak of ISC to 140.367.2% (+8-CPT-
29-O-Me-cAMP: 24.5461.26 mA/cm
2, p,0.05, n=4–6), but the
second peak was not significantly potentiated. Sp-6-Phe-cAMP is a
potent PKA activator. However, it does not activate Epac and thus
can serve as an Epac negative control [23,24]. Sp-6-Phe-cAMP
potentiated the first peak of ISC but not the second peak. The first
peak of ISC was increased to 128.166.6% of the control response
(+Sp-6-Phe-cAMP: 22.4261.15 mA/cm
2, p,0.05, n=4–6).
To test the inhibitory effect of different CysLT1 antagonists,
montelukast, pranlukast, or zafirlukast (1 mM) were added together
with various potentiators (1 mM) 10 min prior to the addition of
UDP (100 mM). As summarized in Fig. 5F, the UDP-evoked ISC
(first peak) in the presence of cAMP elevating agents (forskolin and
8-Br-cAMP), Epac (8-CPT-29-O-Me-cAMP) or PKA (Sp-6-Phe-
cAMP) activator was suppressed by different CysLT1 antagonists.
Pranlukast inhibited the effects of forskolin (43.766.0% of
control), 8-Br-cAMP (42.166.1% of control), and 8-CPT-29-O-
Me-cAMP (33.669.6% of control). Zafirlukast inhibited the effect
of 8-Br-cAMP (63.065.3% of control) and Sp-6-Phe-cAMP
(70.364.2% of control). Montelukast did not possess any
inhibitory effects. None of the CysLT1 antagonists inhibited the
second peak of ISC (data not shown). Taken together, pranlukast
may inhibit the UDP-induced first peak ISC mediated by Epac,
while zafirlukast is likely to inhibit the effect mediated by PKA.
Montelukast, however, does not exert similar inhibitory action.
Pranlukast, but not montelukast or zafirlukast, inhibited
the activation of Epac
To examine whether the inhibitory action of pranlukast occurs
through Epac, we monitored Epac1 activation by using a cyan
fluorescent protein (CFP)-Epac-yellow fluorescent protein (YFP) fusion
construct, which has been used by others to detect real-time changes in
[cAMP] via a fluorescence resonance energy transfer (FRET)-based
approach [25–27]. Fig. 6A shows that 16HBE14o- cells were
successfully transfected with the fusion construct of CYP-Epac-YFP,
which is sensitive to the dynamic changes of [cAMP]. As expected, the
Epac activator 8-CPT-29-O-cAMP (50 mM) evoked about a 20%
increase in the CFP/FRET emission ratio, which indicates a global
Figure 5. Inhibition by CysLT1 receptor antagonists of the potentiating effect of cAMP and Epac on UDP-evoked ISC. Representative
recordings of ISC showing the response to the apical application of 100 mM UDP alone (A) or in combination with pretreatment of the epithelia with
1 mM forskolin (B), 8-Br-cAMP (C), 8-CPT-29-O-Me-cAMP (D), or Sp-6-Phe-cAMP (E) 10 min prior to the application of UDP. (F) Summarized data
showing the potentiating effect of cAMP or Epac on UDP-evoked ISC could be inhibited by different CysLT1 receptor antagonists. Control refers to the
ISC responses of the epithelia to UDP in the presence of various potentiating agents. Each column represents the mean 6 S.E. (n=4–6). (*, p,0.05,
one-way ANOVA with Bonferroni post-hoc test compared with control).
doi:10.1371/journal.pone.0022363.g005
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activation of Epac mediated by 8-CPT-29-O-cAMP. Fig. 6D summa-
rizes the inhibitory effects of montelukast, pranlukast, and zafirlukast.
In the presence of pranlukast (1 mM), the increase in the CFP/FRET
emission ratio induced by 8-CPT-29-O-cAMP was reduced to 45.5% of
the control (p,0.05, n=8).Montelukast(1mM) and zafirlukast (1 mM)
exhibited no inhibitory effects (p.0.05, n=8–10). In the control
experiments, addition of montelukast, pranlukast or zafirlukast (1 mM)
did not induce any discernible increase in FRET ratio (n=3).
Zafirlukast, but not montelukast or pranlukast, inhibited
UDP-activated PKA activity
The cAMP-dependent pathway underlying the inhibitory effects
of montelukast, pranlukast, and zafirlukast on UDP was also
studied by a PKA activity assay. PKA activity in 16HBE14o- cells
was measured by a PKA assay that measures the phosphorylation
of Kemptide, a synthetic substrate specific for PKA. The PKA
activity was measured as a function of fluorescence intensity. As
shown in Fig. 6E, phosphorylated peptides migrated towards the
positively charged anode. The application of 100 mM UDP for
5 min significantly increased PKA activity by 150.0620.2% when
compared with that in untreated cells. The UDP-induced PKA
activity was suppressed after pretreatment with zafirlukast (1 mM)
to 82.0615.1% (p,0.05, n=4), whereas montelukast (1 mM) and
pranlukast (1 mM) did not significantly inhibit UDP-induced PKA
activity. Summarized data are shown in Fig. 6F. Addition of
montelukast, pranlukast, zafirlukast, LTC4 or LTD4 (1 mM) did
not significantly affect the PKA activity of the 16HBE14o- cells
Figure 6. Effects of CysLT1 receptor antagonists on Epac activation and PKA activity. (A) The monochrome CFP and FRET images showing
the cytosolic distribution of the fluorescent Epac probe in 16HBE14o- cells transfected with CFP-Epac-YFP. (B) Representative pseudocolor images of
CFP/FRET emission ratios before and after the addition of 8-CPT-29-O-Me-cAMP. (D) Real-time cAMP changes (normalized CFP/FRET emission ratio)
recorded in cells stimulated with 50 mM 8-CPT-29-O-Me-cAMP with or without 1 mM pranlukast shown in (B). The agents were added at time zero. (C)
Summarized data showing the effect of CysLT1 receptor antagonists on the CFP/FRET emission ratio. Each column represents the mean 6 S.E. (n=8–
10). (*, p,0.05, Student’s t-test compared with control). (E) Confluent 16HBE14o- cells were treated with either vehicle alone (control), 100 mM UDP,
or UDP with different CysLT1 receptor antagonists (1 mM) for 5 min. PKA activity was measured as a function of fluorescence intensity. (F) Summarized
data showing the relative fluorescence level as compared with the control level. Each column represents the mean 6 S.E. (*, p,0.05, n=4, one-way
ANOVA with Bonferroni post-hoc test).
doi:10.1371/journal.pone.0022363.g006
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p.0.05).
Expression of Epac in 16HBE14o- cells
As our data suggest pranlukast inhibited the activation of Epac, we
further studied the distribution of endogenous Epac 1 and Epac 2 in
16HBE14o- cells by immunostaining (Fig. 7). Epac 1 staining (red) of
16HBE14o- cells was mostly localized to the cytoplasm of 16HBE14o-
cells. The signal intensity of Epac 1 was stronger than that of Epac 2,
which may suggest a higher and more uniform expression of Epac 1 in
these cells. In the control experiment, omission of the primary
antibodies resulted in a complete loss of the immunofluorescence.
Discussion
Crosstalk between CysLT1 receptor and P2Y6 receptors
In the airway, Cl
2 secretion and Na
+ reabsorption can be
modulated by the activation of multiple P2Y receptors. The
coordinated regulation of Cl
2 secretion and Na
+ reabsorption is
necessary to maintain the thickness and composition of airway
surface liquid, which in turn affects airway mucus clearance [28].
We have demonstrated previously that 16HBE14o- cells express
multiple P2Y receptors, including P2Y1, P2Y2, P2Y4, and P2Y6.
When activated by UDP, P2Y6 receptors are coupled to Ca
2+- and
cAMP-dependent pathways, thereby leading to transepithelial Cl
2
secretion [11]. Recently, it was discovered that crosstalk exists
between P2Y6 and CysLT1 receptors [6,29]. CysLT1 is the
receptor of CysLTs, which are key mediators of airway
inflammatory disorders. Both P2Y and CysLT1 receptors belong
to the superfamily of G protein-coupled receptors (GPCRs), and
previous studies have suggested functional and structural similar-
ities between these two receptors [30]. CysLT1 receptor
antagonists inhibit the effects of nucleotides acting at P2Y
receptors in monocyte-macrophage-like cell lines [10]. CysLT1
receptor antagonists inhibit UDP- but not carbachol-induced
[Ca
2+]i increases, suggesting that the antagonists specifically
Figure 7. Immunolocalization of Epac 1 and Epac 2 in 16HBE14o- cells. With the use of specific antibodies, immunofluorescence staining of
Epac 1 (A) and Epac 2 (C) were localized to the cytoplasm of 16HBE14o- cells, as indicated by the red colour. Under the conditions specified in the
Methods section, the signal intensity of Epac 1 was stronger than that of Epac 2, which may suggest a higher and more uniform expression of Epac 1
in these cells. In the negative control (E), omission of the primary antibodies resulted in a complete loss of the immunofluorescence. The
corresponding images taken in brightfield were shown in B, D and F.
doi:10.1371/journal.pone.0022363.g007
CysLT1 Receptor Antagonists and P2Y6 Receptor
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22363interact with the P2Y receptor signaling pathway. However, the
detailed molecular mechanism underlying the inhibition remains
unresolved. More importantly, whether similar inhibitory effects
could be observed in human airway epithelia remains unknown. In
the present study, the effects of three specific CysLT1 antagonists
on P2Y6 receptor-mediated signaling pathways and ion transport
in human bronchial epithelial 16HBE14o- cells were examined.
In this study, the protein expression of P2Y6 and CysLT1
receptors in 16HBE14o- cells was demonstrated by western
blotting. Activation of apical P2Y6 receptors by UDP elicited a
concentration-dependent increase in both ISC and [Ca
2+]i,
confirming their role in stimulating transepithelial Cl
2 secretion
in human airway epithelia [11,18,31]. However, stimulation of the
CysLT1 receptors with LTC4 or LTD4 failed to elicit any receptor-
mediated [Ca
2+]i or ISC increases. The CysLT1 receptor is
primarily coupled to Gq/11 protein, which leads to activation of
the PLC/IP3 pathway with intracellular Ca
2+ mobilization in
different cell types [30]. In cells that express both types of
receptors, the addition of LTD4 and UDP caused a robust increase
in [Ca
2+]i [7], and LTC4 could cross-desensitize UDP receptors
[6]. In addition, 16HBE14o- cells possess an active biosynthetic
pathway for the production of leukotrienes, such as LTC4 [32].
Profita et al. have shown that 16HBE14o- cells expressed
functional CysLT1 receptors that coupled to the STAT-1 signaling
pathway. The authors, however, had to enhance the expression of
CysLT1 receptor by transfecting the cells with a construct
encoding the receptor to circumvent the low and variable receptor
expression in the cells [33]. Therefore, the fact that no CysLT1
receptor-mediated [Ca
2+]i response was observed in this study may
be related to the low-level expression of the receptor, or the
receptor may be coupled less efficiently to Gq/11 protein.
Moreover, the CysLT1 receptor agonists (LTC4 and LTD4) and
antagonists (montelukast, pranlukast and zafirlukast) at 1 mM had
no effect on either FRET ratio or PKA activity. These data further
suggest that 16HBE14o- cells do not possess functional CysLT1
receptors. However, we could not exclude the possibility that the
CysLT1 receptor may still couple to other cellular signaling
pathways without interfering with the P2Y6 receptor -mediated
Ca
2+ and ISC responses.
CysLT1 antagonists inhibited UDP-induced ISC
To examine whether the CysLT1 antagonists would have any
effect on P2Y6 receptor-mediated ion transport processes, the
effects of three commonly used CysLT1 antagonists, montelukast,
pranlukast, and zafirlukast, on UDP-induced ISC were examined.
They are potent and selective CysLT1 receptor antagonists
marketed for the treatment of asthma [34] and are sold under
the trade names of Singulair, Ultair, and Accolate, respectively
[35]. The cells were pretreated with CysLT1 antagonists 10 min
before addition of UDP. In general, all three CysLT1 antagonists
inhibited the first peak of UDP-induced ISC, with montelukast
inhibiting the peak at a lower concentration than that of
pranlukast and zafirlukast. However, the second ISC peak was
not influenced by these antagonists. Therefore, all three CysLT1
receptor antagonists, when applied to the apical but not
basolateral side of the epithelia, are capable of inhibiting the
transient but not the sustained component of the ISC, resulting in
the inhibition of Cl
2 secretion across the airway epithelia.
Montelukast inhibited UDP-induced [Ca
2+]i
Recently, we have demonstrated that P2Y6 receptors couple to
both cAMP- and Ca
2+-dependent pathways in 16HBE14o- cells
[11]. For the Ca
2+-dependent pathway, upon the coupling of UDP
to P2Y6 receptors, there is an elevation of [Ca
2+]i, which is caused
by the activation of PLC and thus an increased production of IP3.
In our experiments, upon the addition of UDP, there was a
concentration-dependent increase in [Ca
2+]i. Unlike the biphasic
ISC response, the UDP-induced [Ca
2+]i response is monophasic.
For the [Ca
2+]i measurements, the cells were stimulated with UDP
in a Ca
2+-free solution to remove the complication and
involvement of Ca
2+ influx. The results demonstrated that only
montelukast inhibited the UDP-evoked [Ca
2+]i increase, indicat-
ing that montelukast interferes with UDP-coupled calcium
mobilization. Our data are partly consistent with those of a
previous study showing similar inhibition by montelukast in a
human monocyte-like cell line [10]. However, in our study,
pranlukast did not cause any concentration-dependent inhibition
of [Ca
2+]i change. Therefore, the inhibitory effect of CysLT1
antagonists on P2Y6-coupled calcium signaling pathway may be
cell type-specific. Additionally, the inhibitory effect appears to be
specific to the P2Y6 receptor, as montelukast failed to inhibit the
P2Y2/P2Y4 receptor-mediated increases in [Ca
2+]i and ISC. The
cellular mechanism underlying the effect of montelukast was
further investigated in 16HBE14o- cells treated acutely with
pharmacological agents inhibiting the P2Y6-PLC-IP3-Ca
2+-signal-
ing cascade at different levels. For the first series of experiments,
the most downstream target, IP3 receptors, was inhibited by XeC,
a novel blocker of the IP3 receptor [17]. In the presence of XeC,
the UDP-induced [Ca
2+]i increase was inhibited. However,
coincubation of a low concentration of XeC and montelukast
did not cause an additional inhibition of the UDP-induced [Ca
2+]i
increase when compared with the inhibition caused by montelu-
kast alone. The data suggest that montelukast may interfere with
the pathway at a level upstream of the IP3-induced Ca
2+ release.
U73122, a specific inhibitor of PLC [16], also reduced the UDP-
induced [Ca
2+]i increase. Similarly, coincubation of a low
concentration of U73122 and montelukast failed to induce
additional inhibition of the UDP-induced [Ca
2+]i increase when
compared with the inhibition caused by montelukast alone. The
data rule out the possible interference of montelukast on PLC
activity. Moreover, our data showed that only montelukast applied
at the apical but not basolateral compartment could inhibit the
[Ca
2+]i increase induced by UDP. Therefore, montelukast is likely
to interfere with the pathway at a level upstream of PLC activity
and the production of IP3, probably at the receptor level. It has
been proposed that the functional inhibition of nucleotide-elicited
effects by leukotriene antagonists was mediated through direct
allosteric interaction with the P2Y receptor [10], which is
phylogentically related to CysLT receptors [36]. However, the
detailed molecular interaction remains unknown and requires
further investigation. Another possibility is that the CysLT1
antagonists exerted their inhibitory effects via an as yet
unidentified signaling mechanism common to P2Y6 receptors,
but not characteristic of other P2Y receptor subtypes.
Pranlukast and Zafirlukast inhibited UDP-induced ISC via
different mechanisms
Airway epithelial Cl
2 secretion is stimulated by two important
cytosolic second messengers, [Ca
2+]i and cAMP, and the latter
could also potentiate Ca
2+-mediated Cl
2 secretion in intestinal
T84 cells [37]. PKA and Epac are two downstream targets of
cAMP that transduce diverse cellular actions [12,38]. In intestinal
epithelial cells, cAMP/PKA may potentiate Cl
2 secretion by
phosphorylating apical cystic fibrosis transmembrane conductance
regulator (CFTR) Cl
2 channels. Other potential targets include
basolaterally located Na
+/2Cl
2/K
+ cotransporters or cAMP-
dependent K
+ channels [39]. The effect of Epac on epithelial Cl
2
secretion or ion channel activity is less well understood. A recent
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2 secretion
via a PKA-independent mechanism by stimulating the PLC/IP3-
mediated calcium signaling pathway in intestinal epithelial T84
cells [21]. However, we were not able to detect any increase in
[Ca
2+]i induced by Epac activators (Ko et al., unpublished data).
The addition of forskolin also could not stimulate any increase in
[Ca
2+]i in 16HBE14o- cells [11]. In this study, we investigated
whether the three CysLT1 receptor antagonists interfered with the
potentiating effects of cAMP and Epac on UDP-mediated Cl
2
secretion. Cells were treated with drugs activating the adenylate
cyclase-cAMP-PKA/Epac signaling cascade at different levels.
Firstly, two general cAMP level elevators, forskolin and 8-Br-
cAMP, were used. Forskolin is an adenylyl cyclase activator, while
8-Br-cAMP is a cAMP analog; therefore, both could increase the
intracellular level of cAMP. The first and second peaks of the ISC
response were potentiated by forskolin and 8-Br-cAMP. Our data
demonstrated that pranlukast and zafirlukast inhibited the first
peak of the UDP-induced ISC potentiated by forskolin or 8-Br-
cAMP. However, montelukast did not inhibit the first peak of
potentiated ISC. On the other hand, the second peak of the
potentiated ISC was not inhibited any of the three CysLT1
antagonists. The data demonstrated that the the UDP-evoked Cl
2
secretion potentiated by the presence of various cAMP elevating
agents was inhibited by pranlukast and zafirlukast but not
montelukast.
As mentioned above, cAMP has two downstream targets, PKA
and Epac, which cannot be distinguished by general cAMP level
elevators. Thus, 8-CPT-29-O-Me-cAMP, a specific activator of
Epac [22], was used to investigate the effect of CysLT1 antagonists
on Epac-potentiated ISC induced by UDP. 8-CPT-29-O-Me-cAMP
potentiated the first peak but not the second peak of the UDP-
induced ISC. The 8-CPT-29-O-Me-cAMP-potentiated first peak of
UDP-induced ISC was inhibited only by pranlukast. It appears that
pranlukast could reduce the ISC response potentiated through the
action of Epac. There are two possibilities for the inhibitory
mechanism. Pranlukast may inhibit the UDP-induced ISC through
inhibition of cAMP production or Epac activation. However, it is
unlikely that pranlukast inhibits the production of cAMP because
pranlukast also inhibited the UDP-induced ISC potentiated by the
general cAMP analog 8-Br-cAMP. To confirm that pranlukast
reduces the ISC response by acting through Epac, FRET was
employed. In the study, we used a FRET-based cAMP indicator,
CFP-Epac-YFP. 8-CPT-29-O-Me-cAMP activated Epac, which
caused a significant increase in the FRET emission ratio. In the
presence of pranlukast, the increase in the FRET emission ratio
elicited by 8-CPT-29-O-Me-cAMP was reduced, indicating that
pranlukast inhibited the activation of Epac. These data further
confirms that pranlukast reduces UDP-evoked responses by acting
through the action of Epac, which is expressed in 16HBE14o- cells
as shown by immunocytochemistry. The expression of Epac 1 but
not Epac 2 in 16HBE14o- cells is consistent with the observation
that Epac 1 mRNA is expressed ubiquitously, whereas Epac 2
mRNA is predominately expressed in the brain and endocrine
tissues [40].
On the other hand, Sp-6-Phe-cAMP served as an Epac-negative
control because it activates PKA but not Epac [23,24]. Sp-6-Phe-
cAMP also potentiated the first peak but not the second peak of
UDP-induced ISC. The UDP-induced ISC first peak potentiated by
Sp-6-cAMP was inhibited by zafirlukast, but not by montelukast or
pranlukast. The cAMP-dependent PKA pathway underlying the
effects of montelukast, pranlukast, and zafirlukast on UDP was
further studied by a PKA activity assay. The data showed that
UDP-induced PKA activity was suppressed only in the presence of
zafirlukast, confirming that zafirlukast could reduce the ISC
response acting through the action of PKA. Taken together, these
findings imply that montelukast, pranlukast, and zafirlukast
differentially inhibited the second messenger-mediated changes
in ISC induced by the apical application of UDP. In particular,
pranlukast could inhibit the cAMP-dependent pathway potentiat-
ed through the action of Epac, while zafirlukast may inhibit the
same pathway potentiated through PKA. Montelukast, however,
does not interfere with the cAMP-dependent pathway. However,
we could not exclude the possibility that the CysLT1 antagonists
may have direct effects on apical Cl
2 channels, which await
further investigation.
P2Y6 receptors and inflammatory response
Aside from regulation of ion transport in various epithelia, P2Y
receptors, including P2Y6, have been implicated as important
players in the initiation, amplification, and spread of acute
inflammation as well as the downregulation of chronic inflamma-
tion [41,42]. Recently, it was shown for the first time that P2Y6
receptors modulate the release of the chemokines CCL20 and IL-8
from human nasal epithelial cells and thereby could alter immune
cell recruitment in airways [43]. The specific agonist for P2Y6
receptors, UDP, stimulates the production of proinflammatory
cytokines in retinal pigment epithelial cells [44] and monocytic
cells [45]. In an ulcerative colitis mouse model, both P2Y2 and
P2Y6 receptor mRNA and protein expression was upregulated in
the inflammatory response of intestinal epithelial cells. Stimulation
of the intestinal epithelial cells with the P2Y6 receptor agonist
UDP resulted in an increased expression and release of IL-8 [46].
Montelukast, pranlukast, and zafirlukast are now widely used
clinically for the treatment of asthma and allergic rhinitis. Our
data suggest that they may act through a mechanism of action that
is independent of CysLT1 receptor antagonism. Therefore, it is
possible that part of the antiinflammatory effect of CysLT1
receptor antagonists in asthma is mediated through the P2Y6-
mediated signaling pathway, hence ameliorating the proinflam-
matory responses. In airway epithelia, it is important to maintain
the volume or height of the liquid (air surface liquid, ASL) that
lines the surface of airway epithelia. Enhancing fluid and
electrolyte transport may improve airway surface hydration and
improve mucus clearance, which is hypersecreted in various
respiratory diseases, such as asthma. Stimulation of various P2Y
receptors, including P2Y6 receptors, will increase Cl
2 secretion
into the lumen of the airway, which subsequently drives water
secretion due to the high water permeability of the airway
epithelia.Therefore, the inhibition of P2Y6 receptor-mediated Cl
2
secretion may have the opposite effect by reducing the hydration
of the airway surface, which therefore compromises the innate
immunity of the airway epithelia.
In summary, our data demonstrate that the three specific
CysLT1 receptor antagonists have different pharmacological
actions against the P2Y6 receptor-mediated signaling pathway in
16HBE14o- cells. Although all antagonists inhibited the UDP-
evoked ISC increase, only montelukast inhibited Ca
2+ signaling,
while pranlukast and zafirlukast inhibited the potentiation effect of
cAMP signaling mediated by Epac and PKA, respectively. The
data showed that these three specific CysLT1 receptor antagonists
are not as highly specific as previously thought, and this may
provide implications for the clinical use of these compounds in
asthma or other inflammatory conditions. Therefore, further
studies should be undertaken to evaluate the efficiency and
underlying cellular mechanisms of the therapeutic rationale. With
respect to this study, the detailed mechanisms of CysLT1
antagonists on inflammation-related P2Y receptors should be
further investigated to uncover the crossregulatory mechanisms
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impact on airway epithelial transport.
Materials and Methods
Cell Culture
All experiments were performed using the immortalized cell line
16HBE14o-, which was derived from bronchial surface epithelial
cells [47]. Standard culture techniques were used as described
previously [11,48]. In brief, cells were maintained in Minimum
Essential Medium with Earle’s salt supplemented with 10% (v/v)
fetal bovine serum, 1% (v/v) L-glutamine, 100 IU/ml penicillin,
and 100 mg/ml streptomycin. Cells were cultured on plastic flasks
coated with fibronectin and collagen (BD Biosciences, San Jose,
CA) and were incubated in humidified 95% air-5% CO2 at 37uC.
Western Blot
Cells grown in culture flasks were lysed in radioimmunoprecip-
itation assay buffer [1% NP-40, 0.1% sodium dodecyl sulfate,
0.5% deoxycholic acid, 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl] supplemented with protease inhibitors [5 mg/ml aprotinin,
1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM
sodium fluoride, 1 mM sodium orthovanadate, 2 mM b-glycer-
olphosphate, 1 mM ethylene glycol tetraacetic acid, 1 mM
ethylenediaminetetraacetic acid]. The cell lysate was collected,
and the supernatant was harvested after centrifugation at
20,0006g for 20 min at 4uC. The total protein content in each
sample was determined using the Bradford assay (Bio-Rad,
Hercules, CA). Forty micrograms of protein were used for western
blotting and separated by 10% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis. Separated proteins were electroblotted
to a polyvinylidene fluoride membrane (Immobilon-P, Millipore
Corporation, Billerica, MA) by using a wet transfer system (Bio-
Rad). Membranes were blocked for 1 h at room temperature by
using 1% bovine serum albumin in phosphate buffered saline
containing 0.05% Tween 20 and incubated overnight at 4uC with
specific CysLT1 receptor polyclonal antibody (1:300, rabbit
polyclonal anti-CysLT1, no. 120500, Cayman Chemical, Ann
Arbor, MI) or P2Y6 receptor antibody (1:200, no. APR-011,
rabbit polyclonal anti-P2Y6, Alomone, Jerusalem, Israel). The
positions of positive bands were detected by incubation with
horseradish peroxidase-conjugated anti-rabbit immunoglobulin G
(Dako, Glostrup, Denmark) and visualized using an enhanced
chemiluminescence detection system (Amersham Biosciences,
Piscataway, NJ). Their apparent molecular masses were calculated
based on prestained sodium dodecyl sulfate polyacrylamide gel
electrophoresis low-range protein standards (Bio-Rad).
Immunocytochemistry
16HBE14o- cells cultured on 12-mm glass coverslips were
rinsed twice with phosphate-buffered saline (PBS) and then fixed
in a 4% (w/v) paraformaldehyde solution for 30 min at 4uC. Cells
were permabilized with 0.5% Triton X-100 in PBS for 15 min and
blocked with 10% fetal calf serum (FCS) in PBS for 30 min at
room temperature. Cells were then incubated overnight at 4uC
with Epac 1 or Epac 2 rabbit polyclonal antibodies (Abcam:
ab21236 or ab21238) at a dilution of 1:200 in the blocking solution
(10% FCS in PBS). At the end of primary antibody incubation,
cells were washed three times in PBS and then incubated with goat
anti-rabbit IgG (H+L) coupled to Alexa FluorH 568 (Invitrogen:
A11011) at 1:400 dilution in PBS for 15 min. After rinsing off the
excess fluorescent dye-labeled secondary antibody, the coverslip
was mounted on a microscopic slide using Shandon Immu-
Mount
TM (Thermo Scientific) and visualized with a Zeiss
Axioskop 2 plus microscope under fluorescent microscopy and
brightfield. Control staining was performed following the above
procedure and differed only in the omission of the primary
antibodies.
Measurement of short-circuit current (ISC)
Confluent 16HBE14o- cells were used to measure ISC as
described previously [37]. The monolayers were cultured on
Transwell-COL membranes (Costar, Cambridge, MA) with a 0.4-
mm pore diameter (culture area 0.2 cm
2), mounted in an Ussing
chamber, and bathed in normal Krebs-Henseleit (K-H) solution.
To generate a favorable gradient for Cl
2 exit, a basolateral-to-
apical Cl
2 gradient was applied across the monolayers by
changing the apical K-H solution to one with a reduced Cl
2
concentration [47]. The potential difference was clamped to
0 mV, and ISC was simultaneously measured using a voltage-clamp
amplifier (VCC MC6; Physiologic Instruments, San Diego, CA). A
transepithelial potential difference of 1 mVs was applied period-
ically, and the resultant change in the current was used to calculate
the transepithelial resistance using Ohm’s law. Cells reached
confluence after 10 days with a resistance greater than 150 V?cm
2.
Measurement of PKA activity
Confluent 16HBE14o- cells grown on 6-well plates were
incubated with vehicle alone or UDP in the presence or absence
of different CysLT1 receptor antagonists for 5 min. The PKA
activity was assayed using the PepTagH non-radioactive cAMP-
dependent protein kinase assay system (Promega, Madison, WI) as
described previously [37]. The phosphorylated and nonpho-
sphorylated samples were separated on a 0.8% agarose gel at
100 V for 15 min. The gel was photographed, and the
fluorescence intensity was quantified by the FluorChem
TM 8000
imaging system.
Measurement of intracellular calcium concentration
([Ca
2+]i)
Calcium signals in cells grown on glass coverslips were
measured as previously described [11,49]. Briefly, cells were
loaded with Fura-2 by incubation (45 min, 37uC) in K-H solution
containing 3 mM Fura-2-AM and 1.6 mM pluronic F127. The
Fura-2 loaded cells were washed with K-H solution, and the entire
coverslip was then transferred to a closed perfusion chamber
mounted on an inverted microscope (Olympus IX70, Center
Valley, PA) equipped with a 620 water immersion objective
(numerical aperture 0.6). The excitation light source was provided
by a multi-wavelength illuminator (Polychrome IV, TILL
Photonics, GmBH, Hilden, Germany) that enables rapid inter-
change between two excitation wavelengths (340 and 380 nm).
The emitted fluorescence was passed through a 400-nm dichroic
mirror, filtered at 510 nm, and then collected using a digital
cooled CCD camera (Quantix, Photometrics, Tucson, AZ).
Images were digitized and analyzed using MetaFluor Imaging
Software (v.7.5, Molecular Devices, Downingtown, PA). Fura-2
ratios were used to represent changes in [Ca
2+]i.
Real-time monitoring of cAMP by FRET
Real-time cAMP changes in living cells were monitored using
CFP-Epac-YPF, an Epac-based polypeptide FRET reporter [27].
FRET imaging experiments were performed using the MetaFluor
Imaging System (with FRET module) similar to that described
above. 16HBE14o- cells were transfected with the Epac-based
cAMP sensor. Cells on glass coverslips were placed on the inverted
microscope and excited at 436 nm. CFP and YFP images were
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Photometrics DV
2 emission splitting system (Photometrics,
Tucson, AZ) including two emission filters (470/30 nm for CFP
and 535/30 m for FRET). Acquired fluorescence images were
background subtracted, and real-time cAMP changes were
represented by normalized CFP/FRET emission ratio similar to
that described by Li et al. [50].
Materials and solutions
The bicarbonate-buffered K-H solution contained the following
components (in mM): NaCl, 117; NaHCO3, 25; KCl, 4.7;
MgSO4, 1.2; KH2PO4, 1.2; CaCl2, 2.5; and D-glucose, 11; its
pH was 7.4 when bubbled with 5% CO2/95% O2. The nominally
Ca
2+-free solution was prepared by omitting Ca
2+ from the above
solution. The low Cl
2 solution (10 mM) was prepared by
isosmotically replacing NaCl, KCl, CaCl2, and MgCl2 with Na-
gluconate, K-gluconate, Ca-gluconate, and Mg-sulfate, respec-
tively. The membrane-permeant acetoxymethylester (AM) forms
of Fura-2 and pluronic F127 were obtained from Molecular
Probes (Eugene, OR). UDP, forskolin, and 8-Br-cAMP were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Before the
use of UDP, this nucleotide (10 mM) was incubated (1 h at 37uC)
in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered sa-
line containing hexokinase (10 IU/ml, Boehringer, Mannheim,
Germany) and 22 mM D-glucose to remove contaminating
nucleotide triphosphates. The resulting solution was then aliquot-
ed and stored at 220uC. Montelukast, pranlukast, and zafirlukast
were purchased from Cayman Chemical. 8-CPT-29-O-Me-cAMP
and Sp-6-Phe-cAMP were obtained from BIOLOG (Bremen,
Germany). All other general laboratory reagents were obtained
from Sigma-Aldrich, and all cell culture reagents were obtained
from Invitrogen (Carlsbad, CA, USA).
Data analysis
Pooled data are presented as means 6 standard errors (S.E.),
and values of n refer to the number of experiments in each group.
Experimentally induced changes (D) in the Fura-2 fluorescence
ratio and ISC were quantified by measuring each parameter at the
peak of a response and subtracting the equivalent values measured
immediately prior to stimulation. Statistical comparisons between
original data before normalization were performed using one-way
analysis of variance with Bonferroni post-hoc test, with a p,0.05
considered significant.
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